Reuters reports that DexCom Inc., a medical device company that is developing technology for diabetes care has filed documents with the SEC (Securities and Exchange Commission) for an initial public offering of “as much as $70 million in common stock”.
According to DexCom, the company’s Continuous Glucose Monitoring System (not an FDA-approved device yet) has two components. One is in vivo implanted sensor that “wirelessly transmits continuous glucose readings to the external receiver.” The other is the DexCom receiver that “shows one, three and nine hour trends as well as current glucose levels.”
Kudos has to be given to the company for this gadget’s design. As you might have noticed, design is routinely the last thing on the mind of medical manufacturers.
More at DexCom…